Answers are grounded in this paper and cite their sources.
Background: Non-pharmaceutical interventions (NPIs) during COVID-19 created population-level immunity debt. Following NPI lifting in China (May 2023), clinicians face unprecedented resurgence patterns of respiratory pathogens with altered age distributions and co-infection dynamics, but comprehensive comparative cytokine profiling across diverse pathogens remains limited. Methods: We conducted a 20-month prospective-retrospective surveillance study (June 2024-January 2026) of 54,902 febrile patients, with nested cytokine profiling (n=187) across 11 groups using a 47-analyte multiplex panel. Random forest machine learning with 10-fold stratified cross-validation identified optimal cytokine panels for pathogen discrimination. Results: Three sequential epidemic waves emerged: Wave 1 (July-August 2024, SARS-CoV-2, n=1,988), Wave 2 (December 2024-March 2025, IAV, n=5,373), and Wave 3 (November 2025-January 2026, IAV+HRV, n=8,567). The 9.5% co-infection rate (2,986 cases) fell within the upper pre-pandemic range. G-CSF and IL-1Ra were universally elevated across all pathogens (1.4- to 100.2-fold and 1.8- to 41.7-fold vs. healthy controls, respectively), serving as broad inflammatory markers. Machine learning classification using five cytokines (MIF, IP-10, RANTES, G-CSF, IL-1Ra) achieved 87.3% cross-validated accuracy (95% CI 82.1-92.4%) for pathogen-group discrimination. IAV exhibited a unique IL-4-dominant profile (105.8-fold elevation, η²=0.84), while MP demonstrated distinct immune suppression (IL-16 and PDGF-BB suppressed 0.5-fold). Co-infections generated supra-additive cytokine amplification (e.g., MIG 36.6-fold in HRV+MP vs. 4.2- to 7.3-fold in single infections) and dysregulated IL-10 anti-inflammatory feedback. Conclusions: Pathogen-specific cytokine signatures enable rapid etiological inference from single plasma samples. G-CSF and IL-1Ra serve as universal ARI screening markers, while IAV-specific IL-4 elevation and MP-specific immune suppression offer diagnostic and therapeutic targets for precision medicine in respiratory infectious diseases.
No takes yet. Share an insight, caveat, or question.
Qin et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: